Quantcast

polyDNA Provides 50% Discount on Gene-Eden-VIR During National Autism Awareness Month

April 6, 2013

polyDNA will be lowering the price of Gene-Eden-VIR by 50% for parents of Autistic children.

Rochester, NY (PRWEB) April 06, 2013

During the month of April, which has been sponsored by the Autism Society as National Autism Awareness Month, polyDNA will be lowering the price of Gene-Eden-VIR. Parents of Autistic children will be able to purchase Gene-Eden-VIR, a natural remedy against foreign DNA, at a 50% discount.

The CDC´s report on Autism says, “More children than ever before are being diagnosed with autism spectrum disorders (ASDs). Like the many families living with ASDs, CDC considers ASDs an important public health concern.” [1]

When a parent of an Autistic child buys Gene-Eden-VIR at full price, he or she can then write in to polyDNA using the E-mail address provided on polyDNA´s website. In that E-mail, that parent should provide a doctor´s note regarding their child´s diagnosis. polyDNA will then refund that parent 50% of the full price of his or her purchase.

Autism rates have gone up by 25% in just two years. In fact, the CDC report marks a 78% increase since its first report on Autism in 2007. Experts call it an epidemic.

The Center for the Biology of Chronic Disease (CBCD) suggested that the cause of the Autism epidemic may be the foreign DNA in vaccines such as the MMR II.

Information regarding DNA fragments contaminating the MMR II is available to the public as a download from the FDA´s website. One can download the vaccine package insert for the MMR II vaccine written by Merck & Co., Inc. which shows that Fetal cell line Wistar RA 27/3, Fetal cell line WI-38, and genetically engineered human albumin are all used in the vaccine. [2]

According to the CDC, “The CDC knows that people want answers to what is causing the increase in the number of children identified with ASDs and so do we.” However, the CDC may be unaware of the relationship between foreign DNA and Autism as explained by the Microcompetition theory.

polyDNA urges CDC officials to become familiar with the Microcompetition theory as described in Dr. Hanan Polansky´s “Purple Book,” which has been available as a free public access download from the CBCD website since 2003. [3]

“At first, I wish to congratulate Dr. Hanan Polansky for his scientific bravery to take such a unique, novel approach to further stimulate our understanding of the origin and establishment of chronic diseases. The philosophy underscored is an excellent one … The amazing correlation between theoretical predictions and observed in vivo effects seem to bring us a step closer to a deeper understanding of such complex biologic processes,” said Dr. Sivasubramanian Baskar, PhD, a Senior Scientist at the National Cancer Institute, NIH.

Microcompetition between the foreign DNA fragments injected into infants through the MMR II vaccine and the child´s own DNA could be the biological mechanism linking the MMR II vaccine to Autism.

polyDNA suggests trying a natural remedy against foreign DNA which may have a positive effect on the autistic child. One such remedy is Gene-Eden-VIR.

To learn more about Gene-Eden-VIR, visit http://www.gene-eden-kill-virus.com.

Reference:

1 – http://www.cdc.gov/features/countingautism/

2 – http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm123789.pdf

3 – http://www.cbcd.net/index.php

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/4/prweb10601486.htm


Source: prweb



comments powered by Disqus